250 related articles for article (PubMed ID: 6395951)
1. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
2. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
5. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
Chan KK; Hong PS; Tutsch K; Trump DL
Cancer Res; 1994 Dec; 54(24):6421-9. PubMed ID: 7987837
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
Struck RF; Alberts DS; Horne K; Phillips JG; Peng YM; Roe DJ
Cancer Res; 1987 May; 47(10):2723-6. PubMed ID: 3552204
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients.
Ren S; Kalhorn TF; McDonald GB; Anasetti C; Appelbaum FR; Slattery JT
Clin Pharmacol Ther; 1998 Sep; 64(3):289-301. PubMed ID: 9757153
[TBL] [Abstract][Full Text] [Related]
10. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
12. PLasma half-life and urinary excretion of cyclophosphamide in children.
Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
[TBL] [Abstract][Full Text] [Related]
13. Accelerated decomposition of 4-hydroxycyclophosphamide by human serum albumin.
Kwon CH; Maddison K; LoCastro L; Borch RF
Cancer Res; 1987 Mar; 47(6):1505-8. PubMed ID: 3815352
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
15. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
Dirven HA; van Ommen B; van Bladeren PJ
Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation.
Fasola G; Lo Greco P; Calori E; Zilli M; Verlicchi F; Motta MR; Ricci P; Baccarani M; Tura S
Haematologica; 1991; 76(2):120-5. PubMed ID: 1937169
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamic analysis of the reaction of phosphoramide mustard with protector thiols.
Seitz DE; Katterjohn CJ; Rinzel SM; Pearce HL
Cancer Res; 1989 Jul; 49(13):3525-8. PubMed ID: 2499418
[TBL] [Abstract][Full Text] [Related]
19. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro.
Hales BF
Teratology; 1989 Jul; 40(1):11-20. PubMed ID: 2763206
[TBL] [Abstract][Full Text] [Related]
20. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
Fetting JH; McCarthy LE; Borison HL; Colvin M
Cancer Treat Rep; 1982 Aug; 66(8):1625-9. PubMed ID: 7105052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
